These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19220247)

  • 1. A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.
    Vaughan CP; Endeshaw Y; Nagamia Z; Ouslander JG; Johnson TM
    BJU Int; 2009 Jul; 104(1):69-74. PubMed ID: 19220247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study.
    Song C; Park JT; Heo KO; Lee KS; Choo MS
    J Korean Med Sci; 2006 Dec; 21(6):1060-3. PubMed ID: 17179687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia.
    Johnson TM; Markland AD; Goode PS; Vaughan CP; Colli JL; Ouslander JG; Redden DT; McGwin G; Burgio KL
    BJU Int; 2013 Jul; 112(1):100-8. PubMed ID: 23448285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
    Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age related pathogenesis of nocturia in patients with overactive bladder.
    Weiss JP; Blaivas JG; Jones M; Wang JT; Guan Z;
    J Urol; 2007 Aug; 178(2):548-51; discussion 551. PubMed ID: 17570424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Bell WA; Amarshi N
    JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
    [No Abstract]   [Full Text] [Related]  

  • 20. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.